全文获取类型
收费全文 | 220篇 |
免费 | 4篇 |
专业分类
儿科学 | 5篇 |
妇产科学 | 3篇 |
基础医学 | 11篇 |
口腔科学 | 5篇 |
临床医学 | 15篇 |
内科学 | 17篇 |
皮肤病学 | 2篇 |
神经病学 | 7篇 |
特种医学 | 96篇 |
外科学 | 28篇 |
综合类 | 5篇 |
预防医学 | 4篇 |
眼科学 | 1篇 |
药学 | 11篇 |
肿瘤学 | 14篇 |
出版年
2022年 | 1篇 |
2021年 | 2篇 |
2019年 | 1篇 |
2018年 | 2篇 |
2015年 | 3篇 |
2014年 | 4篇 |
2013年 | 4篇 |
2012年 | 2篇 |
2010年 | 5篇 |
2009年 | 3篇 |
2008年 | 2篇 |
2007年 | 4篇 |
2006年 | 8篇 |
2005年 | 1篇 |
2004年 | 9篇 |
2003年 | 9篇 |
2002年 | 6篇 |
2001年 | 8篇 |
2000年 | 1篇 |
1999年 | 7篇 |
1998年 | 9篇 |
1997年 | 11篇 |
1996年 | 10篇 |
1995年 | 6篇 |
1994年 | 11篇 |
1993年 | 6篇 |
1992年 | 1篇 |
1991年 | 3篇 |
1990年 | 4篇 |
1989年 | 6篇 |
1988年 | 9篇 |
1987年 | 6篇 |
1986年 | 9篇 |
1985年 | 8篇 |
1984年 | 3篇 |
1983年 | 5篇 |
1982年 | 7篇 |
1981年 | 4篇 |
1980年 | 12篇 |
1979年 | 1篇 |
1978年 | 4篇 |
1977年 | 1篇 |
1976年 | 3篇 |
1975年 | 2篇 |
1973年 | 1篇 |
排序方式: 共有224条查询结果,搜索用时 9 毫秒
91.
Computed tomography of the lumbar facet joints 总被引:10,自引:0,他引:10
92.
Dorothy VM Bishop Georgina Holt Elizabeth Line David McDonald Sarah McDonald Helen Watt 《Journal of Neurodevelopmental Disorders》2012,4(1):3
Background
Many children who are late talkers go on to develop normal language, but others go on to have longer-term language difficulties. In this study, we considered which factors were predictive of persistent problems in late talkers.Methods
Parental report of expressive vocabulary at 18 months of age was used to select 26 late talkers and 70 average talkers, who were assessed for language and cognitive ability at 20 months of age. Follow-up at 4 years of age was carried out for 24 late and 58 average talkers. A psychometric test battery was used to categorize children in terms of language status (unimpaired or impaired) and nonverbal ability (normal range or more than 1 SD below average). The vocabulary and non-word repetition skills of the accompanying parent were also assessed.Results
Among the late talkers, seven (29%) met our criteria for specific language impairment (SLI) at 4 years of age, and a further two (8%) had low nonverbal ability. In the group of average talkers, eight (14%) met the criteria for SLI at 4 years, and five other children (8%) had low nonverbal ability. Family history of language problems was slightly better than late-talker status as a predictor of SLI.. The best predictors of SLI at 20 months of age were score on the receptive language scale of the Mullen Scales of Early Learning and the parent''s performance on a non-word repetition task. Maternal education was not a significant predictor of outcome.Conclusions
In this study, around three-quarters of late talkers did not have any language difficulties at 4 years of age, provided there was no family history of language impairment. A family history of language-literacy problems was found to be a significant predictor for persisting problems. Nevertheless, there are children with SLI for whom prediction is difficult because they did not have early language delay. 相似文献93.
Novel mutations in the SH3BP2 gene associated with sporadic central giant cell lesions and cherubism 总被引:1,自引:0,他引:1
VM Carvalho PF Perdigão FR Amaral PEA de Souza L De Marco RS Gomez 《Oral diseases》2009,15(1):106-110
Central giant cell lesion (CGCL) is a reactive bone lesion that occurs mainly in the mandible, characterized by the multinucleated osteoclast-like giant cells in a background of oval to spindle-shaped mononuclear cells. The etiology is unknown and occurs more commonly in young adults. Cherubism, a rare disease found predominantly in females has histologic characteristics indistinguishable from those of CGCL and is caused by mutations mostly present in exon 9 of the SH3BP2 gene. In this study, we investigated four cases of CGCL and one case of cherubism. DNA was extracted from peripheral blood and tumor tissue and all coding and flanking regions of the SH3BP2 amplified by PCR and directly sequenced to identify underlying mutations. Two novel mutations were found; a heterozygous missense mutation c.1442A>T (Q481L) in exon 11 in one sporadic case of CGCL and a heterozygous germline and tumor tissue missense mutation c.320C>T (T107M) in exon 4 in one patient with cherubism. These findings open a new window to investigate the possible relationship between the pathogenesis of the cherubism and CGCL. 相似文献
94.
Spondylolysis studied with computed tomography 总被引:10,自引:0,他引:10
95.
96.
The Dyggve-Melchior-Clausen syndrome 总被引:3,自引:0,他引:3
97.
98.
V M Herben V R Panday D J Richel J H Schellens N van der Vange H Rosing F D Beusenberg S Hearn E Doyle J H Beijnen W W ten Bokkel Huinink 《Journal of clinical oncology》1999,17(3):747-755
PURPOSE: To evaluate the feasibility of administering topotecan in combination with paclitaxel and cisplatin without and with granulocyte colony-stimulating factor (G-CSF) support as first-line chemotherapy in women with incompletely resected stage III and stage IV ovarian carcinoma. PATIENTS AND METHODS: Starting doses were paclitaxel 110 mg/m2 administered over 24 hours (day 1), followed by cisplatin 50 mg/m2 over 3 hours (day 2) and topotecan 0.3 mg/m2/d over 30 minutes for 5 consecutive days (days 2 to 6). Treatment was repeated every 3 weeks. After encountering dose-limiting toxicities (DLTs) without G-CSF support, the maximum-tolerated dose was defined as 5 microg/kg of G-CSF subcutaneously starting on day 6. RESULTS: Twenty-one patients received a total of 116 courses at four different dose levels. The DLT was neutropenia. At the first dose level, all six patients experienced grade 4 myelosuppression. G-CSF support permitted further dose escalation of cisplatin and topotecan. Nonhematologic toxicities, primarily fatigue, nausea/vomiting, and neurosensory neuropathy, were observed but were generally mild. Of 15 patients assessable for response, nine had a complete response, four achieved a partial response, and two had stable disease. CONCLUSION: Neutropenia was the DLT of this combination of paclitaxel, cisplatin, and topotecan. The recommended phase II dose is paclitaxel 110 mg/m2 (day 1), followed by cisplatin 75 mg/m2 (day 2) and topotecan 0.3 mg/m2/d (days 2 to 6) with G-CSF support repeated every 3 weeks. 相似文献
99.
V M Herben R van Gijn J H Schellens M Schot J Lieverst M J Hillebrand N E Schoemaker M G Porro J H Beijnen W W ten Bokkel Huinink 《Journal of clinical oncology》1999,17(6):1906-1914
PURPOSE: To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of 9-aminocamptothecin (9-AC) in a colloidal dispersion (CD) formulation administered as a 30-minute intravenous (IV) infusion over 5 consecutive days every 3 weeks. PATIENTS AND METHODS: Patients with solid tumors refractory to standard therapy were entered onto the study. The starting dose was 0.4 mg/m(2)/d. The MTD was assessed on the first cycle and was defined as the dose at which > or = two of three patients or > or = two of six patients experience DLT. Pharmacokinetic measurements were performed on days 1 and 5 of the first cycle and on day 4 of subsequent cycles using high-performance liquid chromatography. RESULTS: Thirty-one patients received 104+ treatment courses at seven dose levels. The DLT was hematologic. At a dose of 1.3 mg/m(2)/d, three of six patients experienced grade 3 thrombocytopenia. Grade 4 neutropenia that lasted less than 7 days was observed in four patients. At a dose of 1.1 mg/m(2)/d, four of nine patients had grade 4 neutropenia of brief duration, which was not dose limiting. Nonhematologic toxicities were relatively mild and included nausea/vomiting, diarrhea, obstipation, mucositis, fatigue, and alopecia. Maximal plasma concentrations and area under the concentration-time curve (AUC) increased linearly with dose, but interpatient variation was wide. Lactone concentrations exceeded 10 nmol/L, the threshold for activity in preclinical tumor models, at all dose levels. Sigmoidal E(max) models could be fit to the relationship between AUC and the degree of hematologic toxicity. A partial response was observed in small-cell lung cancer. CONCLUSION: 9-AC CD administered as a 30-minute IV infusion daily times 5 every three weeks is safe and feasible. The recommended phase II dose is 1. 1 mg/m(2)/d. 相似文献
100.